Investigational Clostridium difficile infection treatment granted Fast Track designation

Biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, Acurx Pharmaceuticals announced today that the U.S. Food and Drug Administration has granted Fast Track designation for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI). ACX-362E is a novel, oral antibiotic that recently entered Phase 1 development. ACX-362E is a novel, first-in-class, orally-administered antibacterial. It is ["]

The post Investigational Clostridium difficile infection treatment granted Fast Track designation appeared first on Outbreak News Today.